$15.5 million, three products, and a lab-built copy of the place where blood is born. That is what HexemBio took public on September 15, when the Berkeley- and New York-based longevity company unveiled a three-generation product line on top of a total raise of $15.5 million. The figure is up from the $10.4 million seed round it disclosed in April, when it first came out of stealth. Draper Associates, the lead, stayed in. Hong Kong's Happiness Capital joined, alongside Boost VC.
The funding is the easy part. The mechanism is the story. It argues that the slow failure of hematopoietic stem cells (HSCs) — the cells that rebuild blood and immune tissue — is one of aging's load-bearing problems. Its fix does not edit genes, and it does not force aged cells back into a primitive state. It takes a patient's own HSCs, parks them briefly inside a synthetic version of the human yolk sac, and infuses them back.
CHRONICLE: From yolk sac to first-in-human
─────────────────────────────────────────────────────────────
2023 ────── 2024 ────── 2025 ──────── 2026 ──────── 2027
🔬 🚀 ✅ 💰 🧪
Nature Founded FDA Orphan IND on track First patient
paper Drug (Jul) $15.5M total target (Q1)
published Pre-IND (Jan) 3-gen line
Company disclosures, FDA orphan-designation database, Dealroom.co (2025–2026)
The Niche That Forgets to Age
Blood stem cells do not begin life in bone marrow. They are born in the yolk sac, where a short-lived developmental environment supplies the signals that shape their regenerative capacity. After birth they migrate to the marrow, and that formative niche disappears. Decades later, without it, the cells grow exhausted: they engraft poorly, rebuild immunity slowly, and struggle to sustain blood production.
Its core asset, the Synthetic Human Yolk Sac, recreates that vanished niche outside the body. The founding team showed in a 2023 Nature paper that the platform reproduces the architecture, the molecular signals, and the cell types of the real yolk sac. They also reported that HSCs matured inside it match actual human yolk sac tissue closely enough to rule out coincidence. The method is protected, the company says, by 17 patent applications worldwide, two already granted.
"Most innovations in bone marrow transplant rely on harsh treatments such as high levels of cytokines, or genetic engineering that can stress or exhaust stem cells," said Gabriel Levesque Tremblay, HexemBio's chief executive and co-founder. "Our co-founders asked a different question: what if we simply gave aging stem cells back the environment they had at the beginning of life?"
The commercial bet is narrower than the label. It starts in transplant medicine, where regulators already accept a defined endpoint.
$15.5 million buys an IND and a manufacturing line. It does not buy a market, and it does not buy human data.
Aging Is Not an Indication
The FDA does not recognize aging as a disease, so there is no regulatory pathway to test a therapy against it. The company's answer is to attack an adjacent, well-defined problem first: bone marrow transplant in patients with blood cancers such as AML and ALL, where aged or exhausted HSCs drive graft failure.
On that target the company has a clean paper trail. The lead programme received FDA Orphan Drug Designation for bone marrow transplant on 11 July 2025, according to the agency's own orphan-designation database. It completed a Pre-IND meeting in January 2026 and says its IND submission is on track for 2026, with first-in-human dosing targeted after approval in the first quarter of 2027.
The strategic logic is that a successful Phase I does double duty. It produces the first human safety data on rejuvenated HSCs — evidence the company would need anyway to file a later IND for broader aging indications. Orphan status adds market exclusivity and fee relief on a programme that, on its own, addresses a small patient population.
Three Generations, One Platform
September's announcement was less about a fresh round than about a pipeline. The pipeline now spans three products stacked on the same biology.
| Generation | Format | First target | Stage |
|---|---|---|---|
| Gen 1 | Cell therapy: patient's own HSCs, rejuvenated ex vivo | Bone marrow transplant in blood cancer | IND targeted 2026; first-in-human 2027 |
| Gen 2 | Injectable: carries the niche's signals without collecting cells | Broader stem-cell dysfunction outside transplant | Advanced preclinical |
| Gen 3 | Skin application on the same signalling logic | Skin enhancement | Earlier research |
Pipeline as described by HexemBio and Dealroom.co, September 2026
The sequencing matters. Generation two removes the cell-collection step, which is the most expensive and least scalable part of generation one. If it works, the company moves from a hospital procedure toward something closer to an off-the-shelf injectable. Generation three, aimed at skin, is the first product that touches the consumer longevity market directly — and the first that would compete on price rather than on clinical need.
What $15.5 Million Actually Buys
HexemBio total funding, Sep 2026
Announced with a three-generation product line; Draper Associates led, Happiness Capital joined. · Dealroom.co, 2026
At $15.5 million, the raise sits in the top 10% of all-time early-stage venture rounds for US health startups, according to Dealroom. That is a stronger signal than the headline number suggests. The check came from Draper Associates as lead, with Boost VC and the new Happiness Capital money following. The April seed was sized to carry IND-enabling studies and GMP manufacturing scale-up into the clinical timeline.
“HexemBio discovered a way to renew a patient's own stem cells rather than chemically or genetically reprogramming them,” said Tim Draper, founding partner at Draper Associates. “That kind of foundational biological innovation is exactly the type of high-conviction investment we look for.”
Advisory firepower is part of the pitch. Its board of advisers includes Robert Langer, the MIT Institute Professor and Moderna co-founder, and Peter Barton Hutt, a former FDA chief counsel and current Moderna board member. Joanne Kurtzberg, a leading bone-marrow-transplant clinician at Duke, and David Harris, who founded the first US public cord-blood bank, round out the scientific bench.
What Breaks the Thesis
The animal data has not been replicated in humans. The mechanism paper is under review, not published. The entire approach rests on a niche that is hard to manufacture consistently at scale — which is precisely why the round is funding GMP work, not marketing.
Longevity also carries a credibility tax the sector has earned, and Theranos is the reference every cautious investor reaches for. A single Phase I safety signal in a narrow transplant population will not settle whether rejuvenated stem cells change how humans age. It will establish only that the cells are not harmful in one setting.
There is a second risk inside the pipeline itself. Generation three — skin — is where the science gets hardest to defend and the marketing gets easiest to write. A consumer-facing longevity product built on an unproven mechanism is exactly the shape of story that has burned this sector before.
Turning Points to Watch
The IND submission, still targeted for 2026.
First patient dosed in the first quarter of 2027 — the first human data point on the platform.
The Phase I safety readout, and whether it is strong enough to support a broader aging IND.
First in-vivo data on the Gen-2 injectable, which would show the signals work without cells.